Compare International Business Machines Corp (IBM) vs Mesoblast Limited (MESO) Price & Performance

IBM stock trades at $227.13, up 3.0% today, showing resilience after recent volatility. The company reported strong Q4 2025 and Q1 2026 earnings beats but missed Q2 2026 expectations. Revenue growth accelerated to $67.54B in 2025 with net income margin improving to 15.52%. Technical indicators show bearish momentum with RSI at 71.56 suggesting overbought conditions, while analyst consensus remains positive with a $255.50 price target.

IBM's pivot to hybrid cloud and AI consulting shows promise with $5.5B generative AI bookings, though execution risks persist. The stock offers 12.5% upside to consensus target but faces headwinds from mainframe cyclicality and competitive pressure. Cash flow trends weakened in 2025 with negative net cash flow, requiring monitoring of capital allocation strategy.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.